Back to Search
Start Over
Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway.
- Source :
-
Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2020 Dec; Vol. 26 (14), pp. 1889-1897. Date of Electronic Publication: 2019 Dec 13. - Publication Year :
- 2020
-
Abstract
- Background: Hematopoietic stem cell treatment (HSCT) is a promising treatment option for multiple sclerosis (MS), but detailed safety and efficacy measures are still scarce.<br />Objective: To evaluate the efficacy and safety of HSCT in MS.<br />Methods: Retrospective single-center observational study of all MS patients that underwent HSCT in Norway during January 2015 to January 2018. The primary outcome was no evidence of disease activity (NEDA-3) status.<br />Results: A total of 30 patients with a median follow-up time of 26 months (range: 11-48) were evaluated. In total, 25 (83%) achieved NEDA-3 status, and none received disease-modifying treatment after HSCT. For 13 (43%) of the patients, there were sustained improvement in Expanded Disability Status Scale (EDSS) score, and 10 (33%) were working full time after the treatment, compared to only 1 (3%) before treatment. There were no serious treatment-related complications and was no mortality. Five patients (17%) were diagnosed with an autoimmune thyroid disease after the procedure, and 10 (43%) of the women had amenorrhea lasting >12 months and symptoms of ovarian failure.<br />Conclusion: HSCT in MS is an effective and relatively safe treatment option, with few serious complications and no mortality in Norway, so far. However, long-term adverse event with amenorrhea is a common problem.
Details
- Language :
- English
- ISSN :
- 1477-0970
- Volume :
- 26
- Issue :
- 14
- Database :
- MEDLINE
- Journal :
- Multiple sclerosis (Houndmills, Basingstoke, England)
- Publication Type :
- Academic Journal
- Accession number :
- 31833798
- Full Text :
- https://doi.org/10.1177/1352458519893926